Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications

Haşimoğlu Gürün, Kübra; yegin, zeynep arzu; akçalı, didem; OZKURT, ZÜBEYDE NUR; Tertemiz, Oktay Faysal; Can, Ferda; Dikyar, Asena; Berkiten, Suzan

doi:10.5505/aot.2023.87360

Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications

Kübra Haşimoğlu Gürün, (Gazi Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Zeynep Arzu Yeğin, (Gazi Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye)

Didem Akçalı, (Gazi Üniversitesi, Tıp Fakültesi, Anesteziyoloji Anabilim Dalı, Ankara, Türkiye)

Zübeyde Nur Özkurt, (Gazi Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye)

Oktay Tertemiz, (Gazi Üniversitesi, Tıp Fakültesi, Anesteziyoloji Anabilim Dalı, Ankara, Türkiye)

Ferda Can, (Gazi Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye)

Asena Dikyar, (Gazi Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye)

Suzan Berkiten (Gazi Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye)

ACTA ONCOLOGICA TURCICA

5 0

Yıl: 2023 Cilt: 56 Sayı: 2 Sayfa Aralığı: 125 - 135 Metin Dili: İngilizce DOI: 10.5505/aot.2023.87360 İndeks Tarihi: 09-12-2023

Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications

Öz:

INTRODUCTION: Mucositis is one of the major complications of allogeneic hematopoietic stem cell transplantation with myeloablative conditioning. Several measures have been developed to improve pain palliation and quality of life in transplant recipients. This study was performed to evaluate the association of opioid administration using patient controlled analgesia (PCA) method with early posttranplant complications. METHODS: Medical records of 452 patients [median age: 35(15-67) years, male/female: 285/167] were retrospectively reviewed. RESULTS: PCA was used in 157 patients (34.7%) for median 9(1-24) days. The proportion of patients who received myeloablative conditioning regimen was significantly higher in PCA+ group (p<0.001). Severe mucositis was more common in patients who required PCA administration (p<0.001). Total body irradiation (p<0.001) and methotreaxate prophylaxis (p<0.001) were more frequently used in PCA+ patients. Hypoxia, bleeding, sinusoidal obstruction syndrome, invasive fungal infections, neurotoxicity, hepatotoxicity and nephrotoxicity were significantly more common in PCA+ patients. Duration of hospitalization was significantly longer in PCA+ group (p<0.001). DISCUSSION AND CONCLUSION: Opioid administration with PCA, which was more frequently used in patients who had myeloablative conditioning and mucositis, was found to be associated with the development of early posttransplant complications.

Anahtar Kelime: Patient Controlled Analgesia Myeloablative Conditioning Mucositis Allogeneic Hematopoietic Stem Cell Transplantation Pain Palliation

Mukozit İlişkili Ağrı için Hasta Kontrollü Analjezi Yöntemi Eşliğinde Uygulanan Opioid Tedavisinin Erken Dönem Nakil Komplikasyonları ile İlişkisi

Öz:

Giriş: Mukozit, myeloablatif hazırlama rejimiyle allojeneik kök hücre nakli yapılan hastalarda gelişebilen önemli komplikasyonlardan biridir. Kök hücre nakil alıcılarında ağrı palyasyonu sağlamak ve yaşam kalitesini artırmak için farklı yöntemler geliştirilmiştir. Bu çalışmanın amacı, hasta kontrollü analjezi (HKA) yöntemi eşliğinde uygulanan opioid tedavisinin erken dönem nakil komplikasyonlarıyla ilişkisini araştırmaktır. Gereç ve yöntemler: Toplam 452 hastanın [ortanca yaş: 35(15-67) yıl, erkek/kadın: 285/167] verileri geriye dönük olarak incelendi. Bulgular: Hasta kontrollü analjezi 157 hastada (%34.7) ortanca 9(1-24) gün süreyle uygulandı. HKA+ grupta myeloablatif rejim uygulanan hasta sayısı anlamlı yüksekti (p<0.001). HKA gereksinimi olan hastalarda ağır mukozit gelişiminin daha sık olduğu gözlendi (p<0.001). Tüm beden ışınlaması (p<0.001) ve metotreksat kullanımı (p<0.001) HKA+ grupta daha sıktı. Hipoksi, kanama, sinuzoidal obstrüksiyon sendromu, invaziv fungal enfeksiyonlar, nörotoksisite, hepatotoksisite ve nefrotoksisite HKA+ grupta daha sık görüldü. Hastanede kalış süresi HKA+ grupta anlamlı uzun saptandı (p<0.001). Tartışma: Bu çalışmada, myeloablatif hazırlama rejimi uygulanan ve ağır mukozit gelişen hastalarda daha sık kullanılan HKA eşliğinde opioid uygulamasının erken dönem nakil komplikasyonlarıyla ilişkili olduğu gösterildi.

Anahtar Kelime: Hasta Kontrollü Analjezi Myeloablatif Hazırlama Rejimi Mukozit Allojeneik Kök Hücre Nakli Ağrı Palyasyonu

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Hierlmeier S, Eyrich M, Wölfl M, Schlegel PG, Wiegering V. Early and late complications following hematopoietic stem cell transplantation in pediatric patients–A retrospective analysis over 11 years. PloS One 2018; 13(10): e0204914.
2. Palomo M, Diaz-Ricart M, Carreras E. Endothelial dysfunction in hematopoietic cell transplantation. Clinical Hematology International 2019; 1(1): 45-51.
3. Pagliuca S, Michonneau D, Sicre de Fontbrune F et al. Allogeneic reactivity–mediated endothelial cell complications after HSCT: a plea for consensual definitions. Blood Advances 2019; 3(15): 2424-35.
4. Cutler C, Li S, Kim HT et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non- methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11(5): 383-8.
5. Valeh M, Kargar M, Mansouri A et al. Factors affecting the incidence and severity of oral mucositis following hematopoietic stem cell transplantation. Int J Hematol Oncol Stem Cell Res 2018; 12(2): 142-52.
6. Chaudhry HM, Bruce AJ, Wolf RC et al. The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: a systematic review. Biol Blood Marrow Transplant 2016; 22(4): 605-16.
7. Shouval R, Kouniavski E, Fein J et al. Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2019; 103(4): 402- 9.
8. Elad S, Raber-Durlacher JE, Brennan MT et al. Basic oral care for hematology–oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care in Cancer 2015; 23(1): 223-36.
9. Oh HJ, Hong SY, Jeong YM et al. Drug use evaluation of opioid analgesics in pain management among patients with hematopoietic stem cell transplantation. Blood Res 2020; 55(3): 151-8.
10. Vasquenza K, Ruble K, Chen A et al. Pain management for children during bone marrow and stem cell transplantation. Pain Manag Nurs 2015; 16(3): 156-62.
11. Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
12. Gratwohl A, Stern M, Brand R et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115: 4715-4726.
13. Breivik H, Borchgrevink PC, Allen SM et al. Assessment of pain. Br J Anaesth 2008 Jul;101(1):17- 24.
14. Bacigalupo A, Ballen K, Rizzo D et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
15. Averbuch D, Orasch C, Cordonnier C et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013; 98: 1826-1835.
16. Maertens JA, Girmenia C, Brüggemann RJ et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother 2018; 73: 3221- 3230.
17. Ljungman P, de la Camara R, Robin C et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 2019; 19: e260- e272.
18. Mohty M, Malard F, Abecassis M et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2016; 51: 906-912.
19. Eduardo FP, Bezinelli LM, Gobbi M et al. Retrospective study of the digestive tract mucositis derived from myeloablative and non- myeloablative/reduced-intensity conditionings with busulfan in hematopoietic cell transplantation patient. Support Care Cancer 2019; 27(3): 839-48.
20. Freyer CW, Ganetsky A, Timlin C et al. Leucovorin following methotrexate graft-vs-host disease prophylaxis in myeloablative allogeneic hematopoietic transplantation shortens the duration of mucositis and hospitalization. Blood 2018; 132(Suppl 1): 5696.
21. Anand A, Anandi P, Jain NA et al. CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation. Support Care in Cancer 2016; 24(2): 815-22.
22. Sengeløv H, Petersen PM, Fog L, Schmidt M, Specht L. Less mucositis toxicity after 6 versus 3 fractions of high-dose total body irradiation before allogeneic stem cell transplantation. Bone Marrow Transplant 2019; 54(8): 1369-71.
23. Schmidt V, Niederwieser D, Schenk T et al. Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI- based allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2018; 53(9): 1188-92.
24. Wardley AM, Jayson GC, Swindell R et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 2000; 110(2): 292-9.
25. McCann S, Schwenkglenks M, Bacon P et al. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high- dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. Bone Marrow Transplant. 2009; 43(2): 141-7.
26. Corbacioglu S, Jabbour EJ, Mohty M. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant 2019; 25(7): 1271-80.
27. Maffini E, Festuccia M, Brunello L, Boccadoro M, Giaccone L, Bruno B. Neurologic complications after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2017; 23(3): 388-97.
28. Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care in Cancer 2007; 15(5): 491-6.
29. Al Mulla N, Kahn JM, Jin Z et al. Survival impact of early post-transplant toxicities in pediatric and adolescent patients undergoing allogeneic hematopoietic cell transplantation for malignant and nonmalignant diseases: recognizing risks and optimizing outcomes. Biol Blood Marrow Transplant 2016; 22(8): 1525-30.

APA	Haşimoğlu Gürün K, yegin z, akçalı d, OZKURT Z, Tertemiz O, Can F, Dikyar A, Berkiten S (2023). Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications. , 125 - 135. 10.5505/aot.2023.87360
Chicago	Haşimoğlu Gürün Kübra,yegin zeynep arzu,akçalı didem,OZKURT ZÜBEYDE NUR,Tertemiz Oktay Faysal,Can Ferda,Dikyar Asena,Berkiten Suzan Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications. (2023): 125 - 135. 10.5505/aot.2023.87360
MLA	Haşimoğlu Gürün Kübra,yegin zeynep arzu,akçalı didem,OZKURT ZÜBEYDE NUR,Tertemiz Oktay Faysal,Can Ferda,Dikyar Asena,Berkiten Suzan Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications. , 2023, ss.125 - 135. 10.5505/aot.2023.87360
AMA	Haşimoğlu Gürün K,yegin z,akçalı d,OZKURT Z,Tertemiz O,Can F,Dikyar A,Berkiten S Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications. . 2023; 125 - 135. 10.5505/aot.2023.87360
Vancouver	Haşimoğlu Gürün K,yegin z,akçalı d,OZKURT Z,Tertemiz O,Can F,Dikyar A,Berkiten S Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications. . 2023; 125 - 135. 10.5505/aot.2023.87360
IEEE	Haşimoğlu Gürün K,yegin z,akçalı d,OZKURT Z,Tertemiz O,Can F,Dikyar A,Berkiten S "Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications." , ss.125 - 135, 2023. 10.5505/aot.2023.87360
ISNAD	Haşimoğlu Gürün, Kübra vd. "Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications". (2023), 125-135. https://doi.org/10.5505/aot.2023.87360

APA	Haşimoğlu Gürün K, yegin z, akçalı d, OZKURT Z, Tertemiz O, Can F, Dikyar A, Berkiten S (2023). Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications. ACTA ONCOLOGICA TURCICA, 56(2), 125 - 135. 10.5505/aot.2023.87360
Chicago	Haşimoğlu Gürün Kübra,yegin zeynep arzu,akçalı didem,OZKURT ZÜBEYDE NUR,Tertemiz Oktay Faysal,Can Ferda,Dikyar Asena,Berkiten Suzan Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications. ACTA ONCOLOGICA TURCICA 56, no.2 (2023): 125 - 135. 10.5505/aot.2023.87360
MLA	Haşimoğlu Gürün Kübra,yegin zeynep arzu,akçalı didem,OZKURT ZÜBEYDE NUR,Tertemiz Oktay Faysal,Can Ferda,Dikyar Asena,Berkiten Suzan Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications. ACTA ONCOLOGICA TURCICA, vol.56, no.2, 2023, ss.125 - 135. 10.5505/aot.2023.87360
AMA	Haşimoğlu Gürün K,yegin z,akçalı d,OZKURT Z,Tertemiz O,Can F,Dikyar A,Berkiten S Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications. ACTA ONCOLOGICA TURCICA. 2023; 56(2): 125 - 135. 10.5505/aot.2023.87360
Vancouver	Haşimoğlu Gürün K,yegin z,akçalı d,OZKURT Z,Tertemiz O,Can F,Dikyar A,Berkiten S Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications. ACTA ONCOLOGICA TURCICA. 2023; 56(2): 125 - 135. 10.5505/aot.2023.87360
IEEE	Haşimoğlu Gürün K,yegin z,akçalı d,OZKURT Z,Tertemiz O,Can F,Dikyar A,Berkiten S "Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications." ACTA ONCOLOGICA TURCICA, 56, ss.125 - 135, 2023. 10.5505/aot.2023.87360
ISNAD	Haşimoğlu Gürün, Kübra vd. "Opioid Administration for Mucositis-related-Pain Using Patient Controlled Analgesia (PCA) Method is Associated with the Development of Early Posttransplant Complications". ACTA ONCOLOGICA TURCICA 56/2 (2023), 125-135. https://doi.org/10.5505/aot.2023.87360